

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • GlaxoSmithKline (topotecan) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Age Concern England • Black Health Agency • British Ethnic Health Awareness Foundation (BEHAF) • Brook • CANCERactive • Cancer Black Care • Cancer Equality • Chinese National Healthy Living Centre • Confederation of Indian Organisations • Counsel and Care • Equalities National Council • Fpa (Family Planning Association) • Gynae C • Helen Rollason Heal Cancer Charity • Help the Aged • Jo's trust – cervical cancer community • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Marie Stopes International (MSI) • Muslim Council of Great Britain • Muslim Health Network • National Cancer Alliance • National Council for Palliative Care • Rarer Cancers Forum • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder Care • Tenovus Cancer Information Centre 	<p><u>General</u></p> <ul style="list-style-type: none"> • Age Concern Cymru • Board of Community Health Councils in Wales • British National Formulary • Cancer Care Cymru • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Public Health Service for Wales • NHS Alliance • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Hospira UK (paclitaxel, cisplatin and carboplatin) • Medac (paclitaxel) • Teva (carboplatin, paclitaxel, cisplatin) • PLIVA pharma (carboplatin, paclitaxel) • Wockhardt (carboplatin, cisplatin, paclitaxel) • Pharmacia (cisplatin) • Bristol-Myers-Squibb (carboplatin and paclitaxel, cisplatin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Collaboration:Gynaecological Cancer Group • Institute of Cancer Research • MRC Clinical Trials Unit

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Women's Health Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Association for Services to the Elderly • British Geriatrics Society • British Gynaecological Cancer Society • British Oncological Association (BOA) • British Psychosocial Oncology Society • British Society for Clinical Cytology • British Society of Colposcopy and Cervical Pathology • Cancer Networks Pharmacists Forum • Cancer Research UK • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Obstetricians and Gynaecologists • Royal College of Pathologists • Royal College of Physicians, Medical Oncology Joint Special Committee • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • City and Hackney Teaching PCT • Department of Health • Hammersmith and Fulham PCT • Welsh Assembly Government 	<ul style="list-style-type: none"> • National Institute for Health Research • National Cancer Research Institute • National Cancer Research Network • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People • The Eve Appeal • United Kingdom Clinical Research Network • WellBeing of Women <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • NHS Centre for Reviews & Dissemination and Centre for Health Economics -York • National Coordinating Centre for Health Technology Assessment <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer • National Collaborating Centre for Women's and Children's Health <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.